IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis
出版年份 2016 全文链接
标题
IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis
作者
关键词
IAP antagonists, TRAIL, BRAF inhibitors, BCL2 inhibitors, Synergistic treatments, Overcome resistance in colorectal cancer cells
出版物
BMC CANCER
Volume 16, Issue 1, Pages -
出版商
Springer Nature
发表日期
2016-08-12
DOI
10.1186/s12885-016-2606-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant
- (2015) Z Zakaria et al. BRITISH JOURNAL OF CANCER
- Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study
- (2015) Herbert I. Hurwitz et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Molecular Pathways: Leveraging the BCL-2 Interactome to Kill Cancer Cells--Mitochondrial Outer Membrane Permeabilization and Beyond
- (2015) H. Brahmbhatt et al. CLINICAL CANCER RESEARCH
- Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use
- (2015) A. K. Srivastava et al. CLINICAL CANCER RESEARCH
- 5-Fluorouracil preferentially sensitizes mutant KRAS non-small cell lung carcinoma cells to TRAIL-induced apoptosis
- (2015) Haizhen Wang et al. Molecular Oncology
- An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer
- (2015) D. M. Janzen et al. Nature Communications
- Combining TRAIL with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling
- (2015) Grazia Saturno et al. Oncotarget
- BRAF vs RAS oncogenes: Are mutations of the same pathway equal? Differential signalling and therapeutic implications
- (2015) Eftychia Oikonomou et al. Oncotarget
- Birinapant, a Smac-Mimetic with Improved Tolerability for the Treatment of Solid Tumors and Hematological Malignancies
- (2014) Stephen M. Condon et al. JOURNAL OF MEDICINAL CHEMISTRY
- AT-406, an IAP Inhibitor, Activates Apoptosis and Induces Radiosensitization of Normoxic and Hypoxic Cervical Cancer Cells
- (2014) Jing Lu et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents
- (2014) Bing Z. Carter et al. JNCI-Journal of the National Cancer Institute
- Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF- B Activation, and Is Active in Patient-Derived Xenograft Models
- (2014) C. A. Benetatos et al. MOLECULAR CANCER THERAPEUTICS
- TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
- (2014) M H Tuthill et al. ONCOGENE
- Temporal and Spatial Evolution of Therapy-Induced Tumor Apoptosis Detected by Caspase-3-Selective Molecular Imaging
- (2013) Q.-D. Nguyen et al. CLINICAL CANCER RESEARCH
- The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells
- (2013) C. Krepler et al. CLINICAL CANCER RESEARCH
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- IAPs on the move: role of inhibitors of apoptosis proteins in cell migration
- (2013) T K Oberoi-Khanuja et al. Cell Death & Disease
- Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism
- (2012) Jennifer L. Allensworth et al. BREAST CANCER RESEARCH AND TREATMENT
- AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer
- (2012) Melissa K. Brunckhorst et al. CANCER BIOLOGY & THERAPY
- TRAIL Signaling and Synergy Mechanisms Used in TRAIL-Based Combination Therapies
- (2012) C. T. Hellwig et al. MOLECULAR CANCER THERAPEUTICS
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Vemurafenib: the first drug approved for BRAF-mutant cancer
- (2012) Gideon Bollag et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting IAP proteins for therapeutic intervention in cancer
- (2012) Simone Fulda et al. NATURE REVIEWS DRUG DISCOVERY
- A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment
- (2011) Qian Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA Resistance
- (2011) Eftychia Oikonomou et al. PLoS One
- Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells
- (2009) S White-Gilbertson et al. ONCOGENE
- Preclinicalversusclinical drug combination studies
- (2008) Ting-Chao Chou LEUKEMIA & LYMPHOMA
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started